Pfizer stock (PFE): why the price rose

  • The Pfizer Inc. (NYSE: PFE) share price rose 1.34% on the previous trading session. That’s why it happened.

The Pfizer Inc. (NYSE: PFE) share price rose 1.34% on the previous trading session. Investors seem to be reacting to a few catalysts.

Pfizer has announced the European Commission for 100 mg and 200 mg doses of Cibinqo (abrocitinib), a once-daily oral inhibitor of Janus kinase 1 (JAK1), for the treatment of moderate atopic dermatitis (AD) to severe in adults who are candidates for systemic therapy. And a 50 mg dose has been approved to treat moderate to severe AD specifically in patients with moderate and severe renal impairment (renal impairment) or some patients receiving treatment with cytochrome P450 (CYP) 2C19 inhibitors.

Plus Pfizer also announced that its board of directors has declared an increase in the quarterly cash dividend on the company’s common shares to $ 0.40 for the 2022 first quarter dividend, payable on March 4, 2022, to holders of common shares of record at the close of business on January 28, 2022. The cash dividend for the first quarter of 2022 will be the 333rd consecutive quarterly dividend paid by Pfizer.


“For adults living with moderate to severe atopic dermatitis, Cibinqo may help relieve the hallmark symptom of intense itching and has been shown to have rapid improvements in skin clearance, extent and severity, compared to placebo. The approval of Cibinqo in the European Union gives me hope for many patients who will have this additional option to help manage the often painful and disruptive symptoms of moderate to severe atopic dermatitis.

– Dr Stephan Weidinger, Professor of Dermatology at the Christian-Albrechts University in Kiel and Deputy Head of the Department of Dermatology at the University Hospital of Schleswig-Holstein, Kiel, Germany

“There have been few therapeutic innovations over the past decade for people in the European Union suffering from the daily discomfort, distress and pain caused by moderate to severe atopic dermatitis. The safety and efficacy established through a rigorous clinical trials program, designed to evaluate the symptom relief measures most important to patients, gives us great confidence in the positive impact that Cibinqo could have on patients. people living with this debilitating immune-inflammatory disease.

– Mike Gladstone, Global President of Pfizer Inflammation & Immunology

“The increase in dividend is a direct reflection of our strong financial performance and our continued confidence in our current product portfolio and R&D pipeline. “

– Dr Albert Bourla, Chairman and CEO of Pfizer

Disclaimer: This content is intended for informational purposes. Before you make an investment, you need to do your own analysis.

Source link

Comments are closed.